Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

Mussetti, Alberto; Bento, Leyre; Bastos‐Oreiro, Mariana; Sansalvador, Blanca Rius; Albó, Carmen; Bailén, Rebeca; Barba, Pere; Benzaquén, Ana; Briones, Javier; Caballero, A; Campos, António; Español, Ignacio; Coll, Christelle Ferra i; López, Sebastián Garzón; Sierra, Pedro Antonio González; Guerra, Luisa Maria; Hernani, Rafael; Iacoboni, Gloria; Ubieto, Ana Isabel Jiminez; Kwon, Mi; Corral, Lucía López; López‐Godino, Oriana; Martı́nez, Carmen; Martínez-Cibrián, Núria; Montoro, Juan; Pérez-Ortega, Laura; Ortí, Guillermo; Ortiz‐Maldonado, Valentín; Pascual, María-Jesús; Perera, María; Pérez‐Martínez, Antonio; Reguera, Juan Luís; Sánchez, Jose M.; Sanz, Jaime; Torrent, Anna; Yáñez, Lucrecia; Varela, María Rosario; Echechipia, Izaksun Ceberio; Caballero, Dolores; Sureda, Anna

doi:10.1038/s41409-023-01949-x

Cited by 6 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the data indicate that CD19-targeted CAR T cells can induce prolonged remissions in patients with B-cell malignancies, frequently with minimal longterm toxicity, and are likely curative in a subset of patients. 16,[36][37][38][39][40][41][42] Despite the high rate of CRs seen with CAR T-cell therapies, only 30%-40% of patients achieve durable remissions. 42,43 Allo-HSCT remains the curable potential in patients with R/R B-cell lymphoma.…”

Section: Discussionmentioning

confidence: 99%

Allogeneic hematopoietic stem cell transplantation for B‐cell lymphoma in Taiwan

Lee,

Lin,

Yao

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is considered for patients with high‐risk B‐cell lymphoma and relapsed or refractory disease. This study aimed to analyze the long‐term follow‐up data of patients who underwent allo‐HSCT in Taiwan. This was a retrospective observational study using data from the Taiwan Society of Blood and Marrow Transplantation database. A total of 105 patients who underwent allo‐HSCT because of high‐risk, relapsed, or refractory disease between 2010 and 2019 were included. Forty‐five percent of the patients previously underwent autologous stem cell transplantation (ASCT). The median follow‐up duration was 18.6 months. The probability of 3‐year progression‐free survival and overall survival (OS) was 34.5% and 37%, respectively. The probability of 1‐year non‐relapse mortality was 31.4%, and the major cause was infection (75.8%). The multivariable analysis showed that not in remission at the time of transplantation and the absence of graft‐versus‐host disease (GVHD) were factors associated with inferior OS. The probability of 3‐year OS in patients with diffuse large B‐cell lymphoma who underwent allo‐HSCT and allo‐HSCT after ASCT was 40.2% and 25.2%, respectively. Allo‐HSCT could be a salvage therapeutic option for relapsed or refractory B‐cell lymphoma. Complete remission at the time of allo‐HSCT and the presence of GVHD are independent variables for overall survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Allogeneic hematopoietic stem cell transplantation for B‐cell lymphoma in Taiwan

Lee,

Lin,

Yao

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Allo-HCT is still considered a curative treatment option for patients with LBCL who relapse or progress after CAR T cells (Mussetti et al 2023). Survival and NRM for allo-HCT in LBCL are summarized in Table 85.9.6.…”

Section: Allogeneic Hctmentioning

confidence: 99%

Large B-Cell Lymphoma

Bento,

Glass,

Schmitz

2024

The EBMT Handbook

View full text Add to dashboard Cite

The most recent WHO classification of tumors of hematopoietic and lymphoid tissues (Alaggio et al. 2022) classifies large B cell lymphomas (LBCL) into diffuse large B cell lymphoma (DLBCL) NOS with distinct morphological and molecular (germinal center B-cell, activated B-cell) subtypes, high-grade B-cell lymphomas (with MYC and BCL2 rearrangements or NOS subtype), and other less frequent subtypes.

show abstract

“…Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been able to confer long-term remission in patients with relapsed or refractory DLBCL and durable disease control through a graftversus-lymphoma effect [14][15][16][17][18][19] ; however, in recent clinical practice, the application of allo-HSCT in patients with relapsed or refractory DLBCL has been declining with the increase of CAR-T and novel immunotherapies 20) . This is very important because the future application of allo-HSCT in patients with relapsed or refractory DLBCL would be enriched for those whose lymphoma has failed CAR-T therapy or other novel immunotherapies, with characteristics of these patients in more advanced disease and poorer performance status [21][22][23] . To clarify which future patients with relapsed or refractory DLBCL are likely to bene t from allo-HSCT and to better de ne the patient populations for CAR-T and novel immunotherapies, we performed a nationwide retrospective analysis of patients in Japan who received allo-HSCT before the era of CAR-T therapy and novel agents.…”

Section: Introductionmentioning

confidence: 99%

Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma

Kato,

Sugio,

Ikeda

et al. 2023

Preprint

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) are curative treatment modalities for diffuse large B-cell lymphoma (DLBCL) because of the intrinsic graft-versus-lymphoma effect. However, limited information is available regarding which patients with relapsed or refractory DLBCL are likely to benefit from allo-HSCT. We retrospectively analyzed data from 1,268 DLBCL patients who received allo-HSCT. The overall survival and progression-free survival (PFS) rates were 30.3% and 21.6% at 3 years, respectively. Multivariate analysis revealed that stable or progressive disease at transplantation, male patient, poorer performance status at transplantation and shorter interval from previous transplantation were associated independently with a lower PFS. Four prognostic factors were used to construct a prognostic index for PFS, predicting 3-year PFS of 55.4%, 43.7%, 20.4% and 6.6%, respectively. The prognostic model predicted relapse rates following allo-HSCT accordingly (P < 0.0001), whereas did not predict transplantation-related mortality (P = 0.249). The prognostic index can identify a subgroup of DLBCL patients whobenefit from allo-HSCT and it is worthwhile to evaluate whether this model is also applicable to patients undergoing allo-HSCT in cases of relapse after chimeric antigen receptor engineered T-cell therapy, although the application of allo-HSCT has been declining with the increase of novel immunotherapies.

show abstract

Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

Cited by 6 publications

References 28 publications

Allogeneic hematopoietic stem cell transplantation for B‐cell lymphoma in Taiwan

Allogeneic hematopoietic stem cell transplantation for B‐cell lymphoma in Taiwan

Large B-Cell Lymphoma

Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma

Contact Info

Product

Resources

About